FOURTH AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENTOncosignature Companion Diagnostic Agreement • November 13th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations
This FOURTH AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT (this “Fourth Amendment”) is effective as of September 30, 2024 (the “Fourth Amendment Effective Date”) by and between:
